Literature DB >> 1955894

Does ageing aggravate parkinsonian disability?

J Blin1, B Dubois, A M Bonnet, M Vidailhet, M Brandabur, Y Agid.   

Abstract

The influence of age of onset of Parkinson's disease on the severity and the pattern of motor symptoms was investigated by comparing the motor scores with and without levodopa therapy in two groups of patients divided according to age of onset (early less than 50, late greater than 60 years) and matched for disease duration (n = 69 in each group, Study I). The baseline score, that is, the motor disability of patients when off levodopa, was similar in the early- and late- onset groups. In contrast, the residual motor score, assessed when the effect of levodopa treatment was maximum and stable, was significantly higher in the late onset group. When the two groups of patients were matched, in addition, for their residual motor score, (n = 54 in each group, Study II), no difference was observed between the early and late onset groups, except for gait disorder which was more severe in older patients. These results suggest that age of onset mainly affects the response to levodopa therapy, because it may increase the prevalence of non-dopaminergic lesions of the brain, including those responsible for gait disorders.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955894      PMCID: PMC1014515          DOI: 10.1136/jnnp.54.9.780

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?

Authors:  A M Bonnet; Y Loria; M H Saint-Hilaire; F Lhermitte; Y Agid
Journal:  Neurology       Date:  1987-09       Impact factor: 9.910

2.  Sixteen-year follow-up of 100 patients begun on levodopa in 1968: emerging problems.

Authors:  J M Cedarbaum; F H McDowell
Journal:  Adv Neurol       Date:  1987

3.  The effect of age of disease onset on neuropsychological performance in Parkinson's disease.

Authors:  M Hietanen; H Teräväinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-02       Impact factor: 10.154

4.  [The L-dopa test in Parkinson's disease].

Authors:  M Esteguy; A M Bonnet; J Kefalos; F Lhermitte; Y Agid
Journal:  Rev Neurol (Paris)       Date:  1985       Impact factor: 2.607

5.  Age-induced cognitive disturbances in Parkinson's disease.

Authors:  B Dubois; B Pillon; N Sternic; F Lhermitte; Y Agid
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

6.  Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa.

Authors:  F Lhermitte; Y Agid; J L Signoret
Journal:  Arch Neurol       Date:  1978-05

7.  Effect of age at onset on progression and mortality in Parkinson's disease.

Authors:  S G Diamond; C H Markham; M M Hoehn; F H McDowell; M D Muenter
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

8.  Dementia in Parkinson Disease.

Authors:  A Lieberman; M Dziatolowski; M Kupersmith; M Serby; A Goodgold; J Korein; M Goldstein
Journal:  Ann Neurol       Date:  1979-10       Impact factor: 10.422

  8 in total
  12 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Healthcare Data Analytics for Parkinson's Disease Patients: A Study of Hospital Cost and Utilization in the United States.

Authors:  Sunanda Mukherjee; Huanmei Wu; Josette Jones
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

Review 3.  Axial disability and deep brain stimulation in patients with Parkinson disease.

Authors:  Alfonso Fasano; Camila C Aquino; Joachim K Krauss; Christopher R Honey; Bastiaan R Bloem
Journal:  Nat Rev Neurol       Date:  2015-01-13       Impact factor: 42.937

Review 4.  Physical, occupational, speech and swallowing therapies and physical exercise in Parkinson's disease.

Authors:  G Ransmayr
Journal:  J Neural Transm (Vienna)       Date:  2011-04-03       Impact factor: 3.575

5.  Motor phenotype classification in moderate to advanced PD in BioFIND study.

Authors:  Lan Luo; Howard Andrews; Roy N Alcalay; Fernanda Carvalho Poyraz; Amelia K Boehme; Jennifer G Goldman; Tao Xie; Paul Tuite; Claire Henchcliffe; Penelope Hogarth; Amy W Amara; Samuel Frank; Margaret Sutherland; Catherine Kopil; Anna Naito; Un Jung Kang
Journal:  Parkinsonism Relat Disord       Date:  2019-06-23       Impact factor: 4.891

6.  Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease.

Authors:  K Hamada; M Hirayama; H Watanabe; R Kobayashi; H Ito; T Ieda; Y Koike; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

7.  Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years.

Authors:  A J Hughes; J P Frankel; P A Kempster; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

8.  Age-related decrease in responsiveness to L-DOPA is not due to changes in dopamine receptor mRNAs or G protein mRNAs.

Authors:  M Murata; Y Aihara; H Yamanouchi; S Yamada; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  Parkinson's disease and healthy aging: independent and interacting effects on action selection.

Authors:  Laura E Hughes; Roger A Barker; Adrian M Owen; James B Rowe
Journal:  Hum Brain Mapp       Date:  2010-02-16       Impact factor: 5.038

10.  Predictive model for falling in Parkinson disease patients.

Authors:  Nilton Custodio; David Lira; Eder Herrera-Perez; Rosa Montesinos; Sheila Castro-Suarez; Jose Cuenca-Alfaro; Patricia Cortijo
Journal:  eNeurologicalSci       Date:  2016-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.